» Articles » PMID: 26010239

Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS

Overview
Journal J Pharm Sci
Publisher Elsevier
Specialties Pharmacology
Pharmacy
Date 2015 May 27
PMID 26010239
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

This study was conducted to determine the number of drugs exhibiting flip-flop pharmacokinetics following oral (p.o.) dosing from immediate-release dosage forms and if they exhibit a common characteristic that may be predicted based on BDDCS classification. The literature was searched for drugs displaying flip-flop kinetics (i.e., absorption half-life larger than elimination half-life) in mammals in PubMed, via internet search engines and reviewing drug pharmacokinetic data. Twenty two drugs were identified as displaying flip-flop kinetics in humans (13 drugs), rat (nine drugs), monkey (three drugs), horse (two drugs), and/or rabbit (two drugs). Nineteen of the 22 drugs exhibiting flip-flop kinetics were BDDCS Classes 3 and 4. One of the three exceptions, meclofenamic acid (Class 2), was identified in the horse; however, it would not exhibit flip-flop kinetics in humans where the p.o. dosing terminal half-life is 1.4 h. The second, carvedilol, can be explained based on solubility issues, but the third sapropterin dihydrochloride (nominally Class 1) requires further consideration. The few drugs displaying p.o. flip-flop kinetics in humans are predominantly BDDCS Classes 3 and 4. New molecular entities predicted to be BDDCS Classes 3 and 4 could be liable to exhibit flip-flop kinetics when the elimination half life is short and should be suspected to be substrates for intestinal transporters.

Citing Articles

Determination of QLNC-3A6 in canine plasma by UHPLC-MS/MS and its application in pharmacokinetic studies.

Chen S, Liu Y, Wang Y, Wen Z, Meng J, Yang Y Vet Q. 2024; 44(1):1-11.

PMID: 39625835 PMC: 11469437. DOI: 10.1080/01652176.2024.2407174.


Commentary: Pharmacokinetic Theory Must Consider Published Experimental Data.

Benet L, Sodhi J Drug Metab Dispos. 2024; 52(9):932-938.

PMID: 38942444 PMC: 11331591. DOI: 10.1124/dmd.124.001735.


Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies.

Cracchiolo M, Davis L, Matiatos A, Davini D, Husnain M, Simpson R Cancer Chemother Pharmacol. 2024; 94(3):361-372.

PMID: 38878208 DOI: 10.1007/s00280-024-04688-y.


Development and optimization of vildagliptin solid lipid nanoparticles loaded ocuserts for controlled ocular delivery: A promising approach towards treating diabetic retinopathy.

Hakim Ramadan A, Elsayed M, Elsayed A, Fouad M, Mohamed M, Lee S Int J Pharm X. 2024; 7:100232.

PMID: 38357578 PMC: 10864762. DOI: 10.1016/j.ijpx.2024.100232.


An Explanation of Why Dose-Corrected Area Under the Curve for Alternate Administration Routes Can Be Greater than for Intravenous Dosing.

Wakuda H, Xiang Y, Sodhi J, Uemura N, Benet L AAPS J. 2024; 26(1):22.

PMID: 38291293 DOI: 10.1208/s12248-024-00887-w.


References
1.
Klecker Jr R, Collins J, Yarchoan R, Thomas R, Jenkins J, Broder S . Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987; 41(4):407-12. DOI: 10.1038/clpt.1987.49. View

2.
Neale M, Brown K, Foulds R, Lal S, Morris D, Thomas D . The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease. Br J Clin Pharmacol. 1987; 24(4):493-501. PMC: 1386312. DOI: 10.1111/j.1365-2125.1987.tb03203.x. View

3.
von Mollendorff E, REIFF K, Neugebauer G . Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol. 1987; 33(5):511-3. DOI: 10.1007/BF00544245. View

4.
Blum M, Liao S, Good S, de Miranda P . Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med. 1988; 85(2A):189-94. View

5.
Bastain W, Boyce M, Stafford L, Morton P, CLARKE D, Marlow H . Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers. Eur J Clin Pharmacol. 1988; 34(5):469-73. DOI: 10.1007/BF01046704. View